Is there a role for tirapazamine in the treatment of cervical cancer?

Bibliography

• Schwartz G. üeber Desensibilisierung Gegen Röentgen- und Radiumstrahlen. Munch Med Wochenschr 1909;24:1-2
   Google Scholar
• Müller C. Ein eneue Behandlungs methode bösartiger Geschwülste. Munch Med Wochenschr 1910;28:1490-3
   Google Scholar
• Gray LH, Conger AD, Ebert M, The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radio 1953;l26:638-48
   Google Scholar
• Tannock IF. The relationship between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 1968;22:258-73
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor. Radiobiological effects. Cancer Res 1987;47:597-601
   PubMed Web of Science ®Google Scholar
• DiSilvestro PA, Ali S, Craighead PS, A Gynecologic Oncology Group phase III randomized trial of weekly cisplatin and radiation versus cisplatin and tirapazamine and radiation in stage IB2, IIA, IIB, IIIB and IVA cervical carcinoma limited to the pelvis [abstract 2]. SGO; 2012
   Google Scholar
• Höckel M, Knoop C, Schlenger K, Intratumoral PO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26(1):45-50
   PubMed Web of Science ®Google Scholar
• McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) 2007;19(6):427-42
   PubMed Web of Science ®Google Scholar
• Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990;50:7745-9
   PubMed Web of Science ®Google Scholar
• Brown JM, Wang LH. Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Design 1998;13:529-39
   PubMedGoogle Scholar
• Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 1993;53:3992-7
   PubMed Web of Science ®Google Scholar
• Zeman EM, Brown JM, Lemmon MJ, SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol 1986;12(7):1239-42
   PubMedGoogle Scholar
• Lloyd RV, Duling DR, Rumyantseva GV, Microsomal reduction of 3-amino- 1, 2, 4-benzotriazine1, 4-dioxide to a free radical. Mol pharmacol 1991;40:440-5
   PubMed Web of Science ®Google Scholar
• Wang J, Biedermann KA, Brown JM. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 1992;52:4473-7
   PubMedGoogle Scholar
• Holden SA, Teicher BA, Ara G, Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst 1992;84(3):187-93
   PubMedGoogle Scholar
• Weitman S, Mangold G, Marty J, Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 1999;43402-8
   PubMedGoogle Scholar
• Treat J, Johnson E, Langer C, Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a Phase II study. J Clin Oncol 1998;16(11):3524-7
   PubMed Web of Science ®Google Scholar
• Von Pawel J, von Roemeling R, Gatzemeier U, Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 2000;18(6):1351-9
   PubMedGoogle Scholar
• Williamson SK, Crowley JJ, Lara PN Jr, Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: southwest Oncology Group Trial S0003. J Clin Oncol 2005;23(36):9097-104
   PubMedGoogle Scholar
• Lee DJ, Trotti A, Spencer S, Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 1998;42(4):811-15
   PubMedGoogle Scholar
• Rischin D, Peters L, Hicks R, Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19(2):535-42
   PubMedGoogle Scholar
• Rischin D, Peters L, Fisher R, Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 2005;23(1):79-87
   PubMedGoogle Scholar
• Rischin D, Peters LJ, O’Sullivan B, Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, Head START): a phase III Trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28(18):2989-95
   PubMed Web of Science ®Google Scholar
• Chemoradiotherapy for Cervical Cancer. Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010(1):CD008285
   Google Scholar
• Aghajanian C, Brown C, O’Flaherty C, Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol 1997;67(2):127-30
   PubMed Web of Science ®Google Scholar
• Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2000;48(3):791-5
   PubMedGoogle Scholar
• Smith HO, Jiang CS, Weiss GR, Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer 2006;16:298-305
   PubMed Web of Science ®Google Scholar
• Maluf FC, Leiser AL, Aghajanian C, Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 2006;16:1165-71
   PubMed Web of Science ®Google Scholar
• Rischin D, Narayan K, Oza AM, A phase I study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. Int J Gynecol Cancer 2010;20(5):827-33
   PubMedGoogle Scholar
• Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 2009;18(1):77-87
   PubMed Web of Science ®Google Scholar